Printed From BioPortfolio.com
Mylan and Momenta Announce Development Strategy for Proposed Biosimilar to Eylea
09:17 EST 5 Jan 2018 | Speciality Pharma Journal
CAMBRIDGE, Mass. and HERTFORDSHIRE, England and PITTSBURGH, Jan. 3, 2018 /PRNewswire/ — Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) and Mylan N.V. (NASDAQ, TASE: MYL) today announced the development strategy for M710, a proposed biosimilar to EYLEA® (aflibercept) injection. EYLEA is the market-leading vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of neovascular (wet) age-related …
Original Article: Mylan and Momenta Announce Development Strategy for Proposed Biosimilar to Eylea
